secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0000950170-24-033455
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences reports FY 2023 net loss $69.1M; $403.5M cash after $200M PIPE
-------------------------------------------------------------------------------

- Q4 2023 net loss $22.8M vs $12.9M; FY net loss $69.1M vs $55.3M.
- Closed $200M PIPE in Feb 2024; pro-forma cash $403.5M to fund operations through at least 2026.
- TYRA-300 Phase 1 SURF301 initial data expected 2H 2024; Phase 2 IND for achondroplasia on track for 2H 2024.
- FDA granted Rare Pediatric Disease Designation for TYRA-300 in achondroplasia (Jan 2024).
- Initiated SURF201 Phase 1 study for TYRA-200 in FGFR2-altered cholangiocarcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/0000950170-24-033455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/tyra-20240319.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-033455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer